Clinical Trials | September 17, 2025
Enveric clears FDA feedback milestone, prepares IND submission for EB-003
IND application for EB-003 expected in early 2026
IND application for EB-003 expected in early 2026
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Subscribe To Our Newsletter & Stay Updated
